Clinical trials: Wet Macular Degeneration
Neovascular (Wet) Age-related Macular Degeneration
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD).
- Trial name
- NCT06346600
- Testing
- SKG0106
- Where
- 10 sites in United States, China
- Volunteers
- 83 people
- Sponsor
- Skyline Therapeutics
Wet Age-related Macular Degeneration (wAMD)
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
This Phase I/IIa study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration.
- Trial name
- NCT06707753
- Testing
- AL-001
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
Age-related Macular Degeneration
A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
- Trial name
- NCT04151212
- Testing
- BAT5906 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Bio-Thera Solutions
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation
Macular Degeneration
Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patients
Patient-reported vision-related quality of life (QOL) outcomes are increasingly incorporated into clinical trials of new treatments for age-related macular degeneration (AMD).
- Trial name
- COSP (NCT03438669)
- Testing
- no intervention
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- Dr. med. Katja Hatz
Wet Macular Degeneration
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- RANTA (NCT02806752)
- Testing
- Triamcinolone Acetonide, Ranibizumab
- Where
- 7 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Wet Age-related Macular Degeneration
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
To assess the use of aflibercept over a 2 year period in VEGF inhibitor naive and prior treated wet AMD patients managed in 'real wold' clinic settings.
- Trial name
- NCT02005133
- Where
- 17 sites in United Kingdom
- Volunteers
- 188 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.
- Trial name
- NCT01926977
- Testing
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823300
- Testing
- Faricimab, Aflibercept
- Where
- 137 sites in United States, Argentina and 19 more
- Volunteers
- 658 people
- Sponsor
- Hoffmann-La Roche
Wet Age-related Macular Degeneration, Retinal Vein Occlusion
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT03790852
- Testing
- KSI-301
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Kodiak Sciences Inc
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects…
- Trial name
- NCT01940887
- Testing
- E10030, bevacizumab or aflibercept
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 645 people
- Sponsor
- Ophthotech Corporation
Age Related Macular Degeneration
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
- Trial name
- NCT04740671
- Testing
- HLX04-O, ranibizumab
- Where
- 126 sites in United States, Australia and 13 more
- Volunteers
- 410 people
- Sponsor
- Shanghai Henlius Biotech
Neovascular Age-related Macular Degeneration(nAMD), Wet Macular Degeneration
LEAP Strategy for Neovascular Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The "wet" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and…
- Trial name
- LEAP (NCT07744204)
- Testing
- Laser photocoagulation, Anti-VEGF agents
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
DME, Retinal Vein Occlusion (RVO)
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases.
- Conditions
- DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration
- Trial name
- NCT07328776
- Testing
- QiLin-assisted, physician only, without QiLin assisted
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Choroidal Neovascular Membrane In Wet Age Related Macular Degeneration And In Pathological Myopia
Optical Coherence Tomography Angiography Criteria Of The Choroidal Neovascular Membrane In Wet Age Related Macular Degeneration And In Pathological Myopia (Comparative Study).
This study aims to compare choroidal neo-vascular membrane criteria in cases of age-related macular degeneration and cases of pathological myopia.
- Trial name
- NCT05562336
- Testing
- Optical coherence tomography angiography
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Sohag University
Wet Age-related Macular Degeneration
Treat and Extend Analysis Trial With Aflibercept in Wet-AMD
This study is a randomized, prospective, exploratory, descriptive, open label, parallel group, post-authorization study designed to describe and evaluate two aflibercept treatment regimens aimed at achieving and maintaining a…
- Trial name
- NCT04113538
- Testing
- Aflibercept
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Michel Giunta
Macular Degeneration
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
The primary purpose of this study is to assess the safety of AdGVPEDF.11D when given to patients with "wet" age-related macular degeneration (AMD).
- Trial name
- NCT00109499
- Testing
- AdGVPEDF.11D
- Where
- 9 sites in United States
- Sponsor
- GenVec
Age-Related Macular Degeneration
Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
Genetic factors of an individual patient may have an impact on Ranibizumab (Lucentis) treatment outcome in patients with Wet Age-Related Macular Degeneration (AMD).
- Trial name
- NCT01676506
- Testing
- Ranibizumab, Ranibizumab Injection
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Russian Academy of Medical Sciences
Wet Macular Degeneration
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to…
- Trial name
- NCT02541084
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Macular Degeneration
Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
Wet age-related macular degeneration is the most common cause of blind registration in the United Kingdom (UK). Standard treatment involves regular eye injections of a drug called ranibizumab (Lucentis).
- Trial name
- MERLOT (NCT01006538)
- Testing
- Epimacular Brachytherapy, Ranibizumab
- Where
- 24 sites in United Kingdom
- Volunteers
- 363 people
- Sponsor
- King's College Hospital NHS Trust